Lung Cancer Screening and Prevention Act of 2023

This bill expands Medicare coverage to include additional FDA-approved lung cancer screening tests beyond the current standard. It allows the Medicare program to cover new preventive screening tests for eligible beneficiaries, determined by the Secretary, with frequency and payment limits set by Medicare. The key mechanism updates Medicare's coverage rules to permit these new tests using the existing national coverage determination process, without requiring additional regulatory steps. This change directly affects Medicare beneficiaries who qualify for lung cancer screening, potentially increasing access to newer, evidence-based screening options. The bill applies to Part B Medicare coverage for screenings provided on or after its effective date.